02 Apr 2020 --- GlaxoSmithKline (GSK) has completed its divestment of its consumer healthcare nutrition products alongside its malted milk hot beverage powder Horlicks in India to Unilever for cash proceeds equivalent to £397 million (US$492.5 million), making for an EBITA of £114.5 million (US$142.0 million). It also follows the completion of GSK’s merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare Limited and Hindustan Unilever Limited (HUL). The move aligns with Unilever’s strategy of increasing its presence in health-food categories. At the same time, GSK states it looks forward to investing in its listed pharmaceuticals business and its over-the-counter (OTC) and oral health brands in India.
